Biotechwert XOMA steigt und steigt und steigt und steigt... - 500 Beiträge pro Seite

[MrGruendlich]

Hallo Leser

Hatte letzte Woche über den Biotechwert XOMA berichtet und ihn mit 9,20 € empfohlen !!!!


ich bleibe meinem Kursziel von 50€ treu .

viel spaß mit dem Wert

MfG MrGruendlich

[BigLinus]

Hi MrGruendlich,

ich hoffe, daß Du mit Deiner längerfristigen Einschätzung von 50 EUR und mehr recht hast, denke aber, daß 30-35 EUR bis zum Herbst realistischer sind.

Hierzu eine Einschätzung vom 01.03.2000:

Sutro & Co. Doubles Xoma Target To $30, Maintains At Buy (XOMA)
(NewsTraders.com)--Sutro & Co. analyst Eugene Melnitchenko doubled his price objective on Xoma Ltd. (XOMA) today to $30 from $15, pointing to the company`s broad biotechnology platforms.
Melnitchenko, who continues to rate Xoma at "buy," also called attention to the company`s strong research and marketing partners, which include Allergan (AGN), Baxter (BAX) and Genentech (DNA), adding that a potential fourth partner may join Xoma on its antifungal Mycoprex project.

Turning to finances, Melnitchenko feels Xoma is in good condition with enough cash to fund its programs over the next two years, although, according to the analyst, Xoma`s partners will be paying for the clinical trials of most of its new products.

Melnitchenko sees some of Xoma`s new offerings being commercialized within the next three years.

Darüberhinaus soll angeblich das Bank- & Investmenthaus Oppenheim ein 6-Monat-Ziel von 40 EUR genannt haben. Hierzu habe ich aber leider keine nähere Quelle.

Ansonsten kann ich nur sagen, keep the fire burning. Ciao

[BigLinus]

XOMA Reports 1999 Financial Results
Tue Feb 29 08:26:00 EST 2000

BERKELEY, Calif., Feb 29, 2000 (BUSINESS WIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced its financial results for 1999. The Company`s net loss for the year ended December 31, 1999, was $45.8 million ($0.87 per share) compared with $47.2 million ($1.16 per share) in 1998. 1998 results included $4.9 million of non-recurring expenses related to the Company`s change in legal domicile and the
in-licensing of certain BPI patents.

Net cash used in operations in 1999 was $43.1 million and the Company finished the year with $18.5 million in cash and investments. Early in 2000, XOMA completed licensing and supply agreements with the Hyland Immuno division of Baxter Healthcare Corporation. This was followed by a common stock private placement financing that raised gross proceeds of $30.7 million. As a result, XOMA now has cash to meet currently anticipated needs for approximately two years.

"The past twelve months have seen a positive fundamental shift in XOMA`s financial position," said Jack Castello, XOMA`s Chairman, President and Chief Executive Officer. "In 1999 we enhanced our existing arrangement with Genentech for anti-CD11a and put in place product development and supply agreements with Allergan in ophthalmic BPI/anti-infectives. Most recently, we have concluded an important agreement with Baxter for NEUPREX(R) in multiple indications. These
arrangements have reduced our burn rate, and along with our recent financing, have positioned XOMA to renew our internal antibody development and licensing programs for ING-1 and Genimune(TM), while continuing our work with additional BPI-related products including Mycoprex(TM) and anti-angiogenic compounds."

Antibody Programs

-- In April 1999, XOMA extended and expanded its collaborative
arrangement with Genentech for the development of the anti-CD11a
monoclonal antibody product. XOMA and Genentech started Phase III
clinical testing in moderate-to-severe psoriasis patients in
December 1999 and have scheduled a Phase I/II study in kidney
transplant patients.

-- XOMA has accelerated the development schedule for its ING-1
monoclonal antibody. ING-1 binds to an antigen found on
colorectal, breast, prostate, pancreas, and other cancer cells
and recruits the host`s immune system cells to kill the tumor
cells.

-- Late in 1999, XOMA engaged ProPharma Partners Inc. as an advisor
to assist in seeking partners for the Genimune(TM) product and
the targeted gelonin fusion technology. The Genimune(TM) product
is a protein fusion of an antibody-based targeting component and
a proprietary cytotoxin, gelonin. It is designed to treat
autoimmune diseases and immune system cancers. The underlying
gelonin fusion technology is also available for outlicensing.

BPI Platform

-- In January 2000, XOMA and Baxter Healthcare announced an
agreement in which Baxter`s Hyland Immuno division acquired the
worldwide rights to NEUPREX(R) (rBPI21) for treatment of
meningococcemia and all future anti-bacterial and anti-endotoxin
indications. The agreement calls for Baxter to fund development
of NEUPREX(R) in multiple indications. In addition to
meningococcemia-related payments of up to $35 million, XOMA will
receive milestone payments on future indications, and royalties
appropriate for a late stage product.

-- In June 1999, the Company concluded licensing and supply
agreements with Allergan Inc., for the use of rBPI in combination
with other anti-infective agents in products to treat ophthalmic
infections. In December, XOMA received its first milestone under
the Allergan agreement, confirming that rBPI21 in combination
with certain antibiotics shows potent in vitro activity against a
variety of gram-positive and gram-negative bacterial strains that
cause eye infections, including antibiotic-resistant strains.

-- XOMA continues to hold discussions with potential partners for
the Mycoprex(TM) antifungal program. The Company is also
advancing a preclinical development program for BPI-derived
anti-angiogenic compounds. These molecules may be useful in the
treatment of tumors and inflammatory diseases.

XOMA develops and manufactures biopharmaceuticals in Berkeley and Santa Monica, California. Medical targets include infectious diseases, immunologic and inflammatory disorders, and cancer. The Company`s extensive experience developing monoclonal antibodies is reflected in the Genentech anti-CD11a collaboration and its own ING-1 and Genimune(TM) products. XOMA has a patented method for antibody humanization and a proprietary cell expression system for manufacturing recombinant proteins (including antibodies) that has been licensed to more than 15 biotechnology and pharmaceutical companies worldwide. The Company`s infectious disease product development platform is BPI (bactericidal/permeability-increasing protein), a human protein with multiple anti-infective properties and part of the body`s defenses against microbial infection. BPI was discovered at New York University School of Medicine (NYU) by Peter Elsbach, MD, and Jerrold Weiss, PhD. XOMA has collaborated with NYU since 1991 to extend and apply BPI-related research to pharmaceutical development. The term "XOMA" may refer to XOMA Ltd, and/or its affiliates. For more information, visit XOMA`s web site at www.xoma.com

Statements in this press release related to the sufficiency of the XOMA`s cash position, existing and potential collaborative and licensing relationships, timing of clinical trials, the regulatory process and other aspects of product development, or that otherwise relate to future periods, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based
on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. These risks, including those related to the timing or results of pending or future clinical trials, changes in the status of the XOMA`s collaborative relationships, uncertainties regarding the legal standards applicable to biotechnology patents, and actions by the U.S. Food and Drug
Administration or the U.S. Patent and Trademark Office, are discussed in the Company`s most recent annual report on Form 10-K and in other SEC filings. Consider such risks carefully in evaluating XOMA`s prospects.



XOMA Ltd.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands except per share data)

Three Months Ended Year Ended
1999 1998 1999 1998

Revenues:
License fees $ 1,750 $ 3,500 $ 2,281 $ 4,318
Collaborative
agreements -- 2,000 -- 2,000
Product sales and
royalties 12 6 80 27
Total revenues 1,762 5,506 2,361 6,345

Operating
Costs and
Expenses:
Research and
development 8,150 11,254 41,454 43,839
General and
administrative 1,524 1,434 6,080 5,430
Other:
License fee -- 2,515 -- 2,415
Change in
domicile -- -- -- 2,500

Total operating
costs
and expenses 9,674 15,203 47,534 54,184

Loss from
operations (7,912) (9,697) (45,173) (47,839)


Other Income
(Expense):
Investment and
other income 237 421 1,159 2,269
Interest and
other expense (457) (348) (1,765) (1,633)

Net loss (8,132) (9,624) (45,779) (47,203)
Preference share
dividends -- (1,045) (55) (2,614)

Net loss available
to common
shareholders $ (8,132) $(10,669) $(45,834) $ (49,817)
Net loss per
common share $ (0.14) $ (0.23) $ (0.87) $ (1.16)
Weighted average
common shares
outstanding 56,385 46,341 52,705 42,895

Distributed via COMTEX.

Copyright (C) 2000 Business Wire. All rights reserved.

[MrGruendlich]

Die XOMA steigt weiter in den USA geht es wieder 13% hoch!!!!

MfG MrGruendlich

[MrGruendlich]

Hi BigLinus

normal würde ich Dir recht geben wenn du sagst das Kursziel ist 30-35€(bis Jahresende),aber da sind dann noch keine neuen Enwicklungen drin.


MfG MrGruendlich

[BigLinus]

"CIBC WORLD MARKETS UPGRADED XOMA LTD. TO A BUY."


Hi XOMA-Gemeinde,

trotz der nicht unerheblichen Gewinnmitnahmen bzw. Mittelabflüsse hin zu den Finanzwerten hat CIBC World Markets auf der Grundlage der Fundamentaldaten sowie dem guten Fortgang in der Produktent- wicklung XOMA Ltd von Halten auf Kaufen hochgestuft.

XOMA ist nach dem "Kurseinbruch" wieder ein guter bis sehr guter Einsteigerwert, denn die vorge- nannten Kursziele zwischen 35 bis 50 EUR (MrGruendlich) zum Jahresende halte ich nachwievor für realistisch und nicht überzogen.

Wie seht Ihr das?

Ich möchte Euch zu zahlreichen Antworten auffordern.

Ciao

[BigLinus]

XOMA in USA trotz positivem Ausblick unter Druck.

Xoma zum Schlußkurs um 1,5$ auf 10,75$ gefallen dies entspricht einem Kursrückgang von 12,24%.

Hierzu meldet Reuters:

Chiron falls on disappointing trial results
Mon Mar 13 13:06:00 EST 2000

NEW YORK, March 13 (Reuters) - Shares of Chiron Corp.
fell 20 percent on Monday after the biotechnology
giant reported that its FGF-2 drug, intended to treat coronary
artery disease, fell short of goals in a clinical trial.
Chiron shares were down 11-15/16 at 48 in morning trade on
the Nasdaq stock market and helped drag down other biotech
issues. But Chiron was still well above its 52-week low of
18-1/2, reached last October.
Chiron, based in Emeryville, Calif., reported on Sunday
that FGF-2 (fibroblast growth factor-2) did not meet its Phase
II clinical trial efficacy goal of improving a patient`s
ability to exercise 90 days after the drug was administered.
The trial was aimed at treating patients who were not
candidates for angioplasty or bypass surgery.
The company report led to at least one downgrade on Wall
Street: Credit Suisse First Boston cut Chiron shares to "buy"
from "strong buy."
Other biotech shares that showed declines on Monday -- but
which have had amazing gains for the year to date -- included
Medarex Inc. , down 8 at 135; XOMA Ltd. , down
9/16 at 11-11/16; and CuraGen Corp. , down 14-31/32 at
151.
Bucking the trend was Hemagen Diagnostics Inc. , up
1, or 32 percent, to 4-1/8 following news that it had received
clearance to market four new products.
Novoste Corp. rose 22 percent, or 8-1/2, to
46-7/8, after it reported clinical trials showing its BetaCath
product, which uses beta radiation inside blood vessels,
prevents clogging of stents, tiny sleeves used to reinforce the
walls of weakened arteries.

[BigLinus]

XOMA develops and manufactures genetically-engineered protein (including antibody) and peptide pharmaceuticals. Medical targets include microbial infections, infectious complications (such as those that may follow trauma or surgery), and immunologic disorders. The Company’s primary drug development platform is BPI (bactericidal/permeability-increasing protein), a human host-defense protein with multiple anti-infective properties.

The BPI Platform has several products in development (see pipeline inside). NEUPREX®, XOMA’s first recombinant BPI-derived product, has recently completed a Phase III trial in severe pediatric meningococcemia. An ophthalmic anti-infective development effort has led to a recent license to Allergan to use recombinant BPI (rBPI) in combination ophthalmic anti-infectives with antibiotics. Additional BPI-derived formulations (e.g., “I-PREX”), are under development for other ophthalmic indications. XOMA is actively seeking a partner for clinical development of its BPI-derived antifungal peptido-mimetics (“Mycoprex”). Additional BPI-derived products are in the research pipeline, including anti-angiogenic and anti-infective compounds.

The Company has considerable experience with therapeutic antibody development. In a unique collaboration, Genentech and XOMA have successfully brought the anti-CD11a (hu1124) antibody through Phase II clinical trials in moderate-to-severe psoriasis patients and started Phase III trials. Clinical testing is also planned in kidney transplant rejection patients. Other XOMA antibodies include ING-1 (targeting cancers) and a targeted immunfusion (TIF) protein, Genimune™ (targeting immunological disorders). XOMA’s patented Human Engineering technology represents a new alternative to CDR-grafting methods for humanization of antibodies.

Three partners in the United States and Japan are developing diagnostics based on XOMA’s LBP (lipopolysaccharide binding protein) assay. XOMA has also granted 17 licenses for its bacterial cell expression system for the manufacture of recombinant proteins. Additional transactions include T cell receptor technology sold to Connetics and anti-CD20 patents licensed to Genentech for IDEC’s Rituxan® product. Over the last three years, XOMA has raised more than $70 million in cash from such arrangements and the Genentech collaboration

XOMA’s business strategy is to develop and manufacture its compounds through human clinical trials and partner products for commercialization and marketing. Therefore, the Company maintains a manufacturing infrastructure for product development from the laboratory to commercial scale.

At the end of 1998, XOMA changed its legal domicile from Delaware to Bermuda (becoming XOMA Ltd.). A wholly owned subsidiary, XOMA (US) LLC, continues to operate the administrative, research & development and manufacturing activities in Berkeley, California, as well as manufacturing research and scale-up facilities located in Santa Monica, California.

XOMA Product Development Pipeline
Trade Name Product Description Indication Status Comments
rBPI-21 IV formulation
(NEUPREX®) meningococcemia Phase III 395 patients, enrollment complete
hemorrhage due to trauma Phase III Halted at 1100 patients
severe intra-abdominal infections Phase I/II dose-related benefits in 21 patients
partial hepatectomy Phase II 35 patient study, article submitted
pulmonary exacerbations in cystic fibrosis patients Phase I 15-patient PK/safety study complete
rBPI-21 combination topical
anti-infectives ophthalmic infections, corneal ulcers Preclinical licensed to Allergan
rBPI-21 topical formulation
(I-PREX(tm)) ophthalmic infections prophylaxis Preclinical Strategic partner discussions
BPI-Derived Peptides fungicidal compounds (Mycoprex(tm)) systemic fungal infections Preclinical Strategic partner discussions
anti-angiogenic chronic infalmmatory diseases, metastatic tumors Preclinical Internal program
antibacterial gram-negative and gram-positive infections Research Internal program
anti-endotoxin endotoxin neutralization Research Internal program

Lipopolysaccharide
Binding Protein (LBP) diagnostic assay endotoxin-associated disorders Clinical Licensed to Biosite, DPC and SRL
hu1124
(Anti-CD11a) humanized monoclonal
antibody moderate to severe
psoriasis Phase II Collaboration with Genentech
kidney transplant rejection Pre-IND Collaboration with Genentech
Expression Technology bacterial and CHO cell expression/secretion systems recombinant protein manufacturing production system Available for licensing 17 licenses to date
Human
Engineering antibody humanization therapeutics Available for licensing Altenative to CDR grafting
ING-1 therapeutic antibody cancer therapeutics and diagnostics Available for licensing Humanization in process
Gelonin Fusion Proteins TIF (targeted immunofusion) (Genimune(tm)) autoimmune disorders
Immunological cancers Available for licensing Strategic partner discussions
Thaumatin recombinant plant-derived protein flavor enhancer FEMA GRAS Approved Available for outlicensing

This fact sheet contains certain forward-looking statements that involve risks and uncertainties.
Such statements are based on XOMA`s current beliefs as to the outcome and timing of future events;
actual events or results may differ materially from the company`s expectations.
For a discussion of risk factors see XOMA`s SEC reports, including but not limited to Forms 10-Q and 10-K.

© Copyright 1999, XOMA

[BigLinus]

`BIO-TECHs` weiterhin unter Druck. Kurz vor Börsenschluß XOMA in USA um $1,1/16 auf $9,11/16 gefallen.


U.S. blue chips steady though biotechs hurting
Tue Mar 14 13:58:00 EST 2000

(Updates to early afternoon)
By Jennifer Westhoven
NEW YORK, March 14 (Reuters) - U.S. technology stocks
traded moderately lower early Tuesday afternoon amid selling,
especially in the biotechnology sector, while blue-chip shares
rose slightly. The technology selloff that began Monday, plus
worries about economic data later this week and next week`s Fed
meeting, unraveled a solid rally under way earlier Tuesday in
both Nasdaq and Dow stocks.
The Nasdaq composite index was down 41 points, or 0.85
percent, at 4,865 after giving up an early gain of 106 points.
The losses followed Monday`s trouncing, when the index was hit
with its fourth-biggest point loss ever. The Nasdaq is now off
3.93 percent from its closing high of 5,048.62 on Friday.
The Dow Jones industrial average was up 6 points, or
0.06 percent at 9,952. Earlier, the index had been up by as
much as 96 points. The Standard & Poor`s 500 Index was down 2
points at 1,381.
"We have a couple of numbers ahead of us and you don`t want
to be blind-sided by any of these events," said Joseph Barthel,
chief investment strategist of Fahnestock & Co. in Great Neck,
N.Y. "So you can expect a contraction in volume as people pull
in their horns."
On Thursday and Friday, Wall Street will get economic
reports on prices at the wholesale and retail level, which
could provide clues to the inflationary picture and the future
direction of interest rates.
On Tuesday of next week, the Federal Reserve`s
interest-rate-setting policy group meets and Wall Street is
betting on a 25-basis-point increase in the federal funds rate.
And on March 27, the world`s eyes will be on Vienna, where the
oil cartel, the Organization of Petroleum Exporting Countries,
is due to meet to decide on future production levels.
Biotechnology stocks were down but off their lows. Human
Genome lost 18-3/16 to 134-3/8, Incyte Pharmaceuticals
fell 46 to 151 and AriadPharmaceuticals Inc.
slipped 3-3/4 to 21-11/16/
However, American Express Co. , one of the 30 stocks
in the Dow average, jumped 5 to 131-6/16. The financial
services company will provide electronic payment services to a
Web-based corporate marketplace being set up by Dell Computer
Corp. and e-commerce company Ariba Inc.
Dell shares rose 2-1/2 to 57-1/4 in heavy Nasdaq trading
and earlier touched a new 52-week high of 57-7/8. Ariba
dropped 1/4 to 297-3/4.
Oracle Corp. rose 2 to 80-3/4. The database
software company said it would team up with Cable & Wireless
HKT of Hong Kong to launch a Web-based electronic
marketplace in China.
Oracle is also due to report its earnings after the close,
with analysts expecting profits of 13 cents a share, compared
with 10 cents in the year-ago period, according to First
Call/Thomson Financial.
Dow component Alcoa Inc. , the world`s largest
aluminum company, stumbled 4-7/8 to 63-3/16 after it agreed to
buy aerospace industry supplier Cordant Technologies Inc.
, in a $2.9 billion deal. Cordant was up 25-3/4 to
55-5/16.
In economic news, February retail sales showed an increase
of 1.1 percent, compared with the 1.0 percent gain expected by
economists polled by Reuters. Excluding autos, retail sales
rose 1 percent, compared with an anticipated gain of just 0.6
percent.
The numbers calmed fears that the Federal Reserve might
aggressively raise interest rates when it meets next Tuesday.
The Fed has increased rates four times since last June.
The 30-year U.S. Treasury bond moved higher, with the price
up 21/32 and the yield, which moves in the opposite direction,
slipping to 6.12 percent from Monday`s close of 6.17 percent.
"This market looks treacherous and choppy for a while,"
Barthel said. "April in Paris is really where you want to be.
Go and fall in love and forget this."
((Jennifer Westhoven Wall Street Newsdesk [phone]))

REUTERS
Rtr 13:59 03-14-00

[BigLinus]

Hi XOMA-Gemeinde,

der Kurs unserer Aktie hat in den USA erneut um $29/64 auf $9, 1/4 nachgegeben. Somit hat XOMA innerhalb einer Woche um 40% an Wert verloren.
XOMA wird somit wieder interessant zum Wiedereinstieg.

Ciao

[BigLinus]

Hi XOMA-Gemeinde,

zum Börsenschluß zeigt sich XOMA in den USA erholt. Der Wert legte dort um $0,75 auf $10 zu.

Ob damit das Tal der Tränen durchschritten ist und es nun wieder stark nach `Norden` geht werden wir sehen. Ich habe jedenfalls gestern ein paar nachgekauft.

Ciao

[BigLinus]

BPI Peptide Program: Mycoprex(tm),
and Other BPI-derived Peptides
Introduction
XOMA Corporation has a pipeline of therapeutic products based on bactericidal/permeability-increasing protein (BPI), a human host-defense protein with multiple anti-infective properties. Scientists at XOMA have identified a number of peptides and peptidomimetics, small molecular derivatives of BPI, that have shown potent activity in five therapeutic areas. XOMA is developing a number of these BPI-derived peptide compounds for pharmaceutical use. XOMA`s current peptide program is focused primarily on developing a BPI-derived antifungal peptide product, and on antiangiogenesis peptides.

What is BPI?
BPI was discovered by XOMA`s collaborators at New York University Medical School and is found in certain white blood cells (neutrophils). As part of the natural host-defense system against bacterial infection, BPI kills and neutralizes gram-negative bacteria, and inhibits angiogenesis (growth of blood vessels).

XOMA scientists found that derivatives of BPI showed all these activities and also enhanced the activity of antibiotics. An injectable formulation of one of these derivatives, NEUPREX®, a systemic formulation of rBPI-21, is now in clinical trials.

BPI-derived Peptides
XOMA scientists discovered three active areas (functional domains) within the N-terminal fragment of BPI (the amino-terminal 199 amino acid fragment). XOMA researchers have identified and characterized a number of peptides (small chains of amino acids) derived from these domains that show potential as new pharmaceuticals. XOMA scientists have derived distinct groups of potent peptides from BPI with five types of bioactivity:

antifungal (kills or inhibits fungi)
antibacterial (kills or inhibits bacteria)
endotoxin-neutralizing (inhibits toxic bacterial molecule)
heparin-neutralizing (inhibits anticoagulant activity of heparin)
anti-angiogenic (inhibits growth of new blood vessels)
XOMA has undertaken a screening program for BPI-derived peptides. A number of peptide compounds have undergone testing in vitro and in vivo for safety and efficacy. A number of these experiments have been presented at ICAAC from 1994 through 1997 (XOMA presentations: ICAAC `96, ICAAC `97, ICAAC `98, ICAAC `99).

Patent Position
XOMA is building a broad patent position related to its work with BPI, including BPI-derived peptides, and now controls more than 50 issued patents in the U.S. and Europe, plus notices of allowance, and applications for more than 20 additional patents.

Near-Term Therapeutic Targets
XOMA is developing active peptide compounds from the BPI platform for the five different pharmaceutical applications. At present, development priority is focused on one group of these peptides that showed potent fungicidal activity against multiple strains of common pathogenic fungi.

A safer and more effective fungicidal than those currently available could be used to treat systemic fungal infections, a growing problem in AIDS patients and others with compromised immune systems. Several antifungal peptide compounds are now in toxicology studies and XOMA is seeking a development partner to collaborate on bringing one of them (to be called Mycoprex(tm)) into the clinic.

Longer-Term Targets
Antiangiogenesis: the company is also developing anti-angiogenic compounds that may be useful in treating ophthalmic conditions, chronic inflammatory conditions or treat tumors by preventing blood vessel growth (angiogenesis).

The antibacterial properties of BPI-derived peptides suggest additional applications. Given the increasing concern over bacterial resistance to antibiotics, antibacterials with a different mode of action could be combined with available antibiotics to overcome antibiotic resistance. XOMA scientists have produced BPI-derived peptides that kill certain gram-positive bacteria and mycoplasma, as well as gram-negative bacteria. A peptide product with a broad spectrum of antimicrobial activity could expand XOMA`s pipeline of infectious disease therapies.

[BigLinus]

Hier eine halbwegs verständliche Übersetzung:

BPI-PeptidProgramm: Mycoprex(tm),
und andere BPI-derivedpeptide
Einleitung
XOMA Corporation hat eine Rohrleitung der therapeutischen Produkte, die auf bactericidal-/permeability-increasingprotein (BPI) basieren, ein menschliches Host-defenseprotein mit mehrfachen antiinfektiösen Eigenschaften. Wissenschaftler an XOMA haben eine Zahl der Peptide und des peptidomimetics, kleine molekulare Ableitungen von BPIS gekennzeichnet, die starke Aktivität in fünf therapeutischen Bereichen gezeigt haben. XOMA entwickelt eine Anzahl von diesen BPI-derivedpeptidmitteln für pharmazeutischen Gebrauch. Wird aktuelles Peptidprogramm XOMA`s hauptsächlich auf dem Entwickeln eines pilzbefallverhütenden Peptidproduktes BPI-derived und auf antiangiogenesispeptide gerichtet.

Was ist BPI?
BPI wurde von den XOMA`smitarbeitern an der New Yorkhochschulmedizinischen Schule entdeckt und wird in bestimmten weißen Blutzellen (Neutrophils) gefunden. Als Teil des natürlichen Host-defensesystems gegen bakterielle Infektion, beendet BPI und neutralisiert gramnegatives Bakterium und hemmt angiogenesis (Wachstum der $blutgefässe).

XOMA-Wissenschaftler fanden, daß Ableitungen von BPI alle diese Aktivitäten zeigten und auch die Aktivität der Antibiotika erhöhten. Eine injizierbare Formulierung von einer dieser Ableitungen, NEUPREX®, eine Körperformulierung von rBPI-21, ist jetzt in den klinischen Versuchen.

BPI-derivedPeptide
XOMA-Wissenschaftler entdeckten drei Beschriftungsbereiche (Funktionsgebiete) innerhalb des N-Terminalfragments von BPI (das Aminosäurefragment des Amino-Terminals 199). XOMA-Forscher haben eine Anzahl von den Peptiden (kleine Ketten der Aminosäuren) berechnet worden von diesen Gebieten gekennzeichnet und gekennzeichnet, die Potential als neue pharmazeutische Produkte zeigen. XOMA-Wissenschaftler haben eindeutige Gruppen der starken Peptide von BPI mit fünf Arten Bioaktivität berechnet:

pilzbefallverhütend (Abbrüche oder hemmt Pilze)
antibakterielles Mittel (Abbrüche oder hemmt Bakterium)
Endotoxin-endotoxin-neutralizing (hemmt giftiges bakterielles Molekül)
Heparin-heparin-neutralizing (hemmt Antigerinnungsmittelaktivität des Heparins)
anti-angiogenic (hemmt Wachstum der neuen $blutgefässe)
XOMA hat sich ein Siebungprogramm für BPI-derivedpeptide aufgenommen. Eine Anzahl von Peptidmitteln haben auf Sicherheit und Wirksamkeit in vitro und in vivo prüfen durchgemacht. Eine Anzahl von diesen Experimenten sind an ICAAC von 1994 bis 1997 dargestellt worden (XOMA-Darstellungen: ICAAC `96, ICAAC `97, ICAAC `98, ICAAC `99).

PatentPosition
XOMA baut eine ausgedehnte Patentposition auf, die auf seiner Arbeit mit BPI, einschließlich der BPI-derivedpeptide in Verbindung gestanden wird und steuert jetzt mehr als 50 herausgegebene Patente in den US und im Europa, Plusbegriffe der Genehmigung und der Anwendungen für mehr als 20 zusätzliche Patente.

Therapeutische Ziele Near-Term
XOMA entwickelt aktive Peptidmittel von der BPI-Plattform für die fünf unterschiedlichen pharmazeutischen Anwendungen. Zur Zeit wird Entwicklung Priorität auf eine Gruppe dieser Peptide gerichtet, die starke pilztötende Aktivität gegen mehrfache Belastungen der allgemeinen pathogenen Pilze zeigten.

Ein sichereres und wirkungsvolleres pilztötendes als jenes zur Zeit verfügbar konnte verwendet werden, um pilzartige körperlichinfektion, ein wachsendes Problem bei AIDS-Patienten und andere mit verglichenen immunen Systemen zu behandeln. Einige pilzbefallverhütende Peptidmittel sind jetzt in den Toxikologiestudien und XOMA sucht einen Entwicklung Partner, um auf dem Holen eine von ihnen (benannt werden Mycoprex(tm)) in die Klinik zusammenzuarbeiten.

Längerfristige Ziele
Antiangiogenesis: die Firma entwickelt auch anti-angiogenic Mittel, die in behandelnden Augenbedingungen, in den chronischen entzündlichen Bedingungen oder in den Festlichkeittumoren nützlich sein können, indem man $blutgefässwachstum (angiogenesis) verhindert.

Die antibakteriellen Eigenschaften der BPI-derivedpeptide schlagen zusätzliche Anwendungen vor. Das wachsende Interesse über bakteriellem Widerstand zu den Antibiotika gegeben, konnten antibakterielle Mittel mit einem anderen Modus der Tätigkeit mit vorhandenen Antibiotika kombiniert werden, um antibiotischen Widerstand zu überwinden. XOMA-Wissenschaftler haben BPI-derivedpeptide, die bestimmtes grampositives Bakterium und Mykoplasma beenden, sowie gramnegatives Bakterium produziert. Ein Peptidprodukt mit einem ausgedehnten Spektrum der antibiotischen Aktivität konnte XOMA`s-Rohrleitung der ansteckenden Krankheittherapien erweitern.

[BigLinus]

Hi XOMA-Gemeinde,

hier eine Übersetzung zu einem anderen Forschungszweig von XOMA.

Blatt Tatsache Meningococcemia
Was ist meningococcemia? Gewußt in Großbritannien und in Europa als Meningokokkenblutvergiftung, ist dieses eine der wenigen bakteriellen Krankheiten, die eine angesteckte Person innerhalb der Stunden beenden können. Zwischen 60-90% aller Fälle treten Sie in den Kindern auf, und Kinder unter fünf sind besonders an der Gefahr.

Was verursacht diese Krankheit? Es wird durch das gleiche meningococcusbakterium, meningitidis Neisseria,die die allgemeinste Ursache der vertrauteren Krankheit sind, Meningitis verursacht. In der Meningitis Bakterium die Entzündung der Membranen, die das Gehirn und Rückenmark umgeben, gezeigt in verursacht das charakteristischem steifem einen Ansatz und hohes Fieber. Meningitis reagiert schnell auf antibiotische Behandlung und permanente Beschädigung ist selten.

Wie ist meningococcemia unterschiedlich? Im meningococcemia dringt das Bakterium den Blutstrom ein. Ein angestecktes Kind stellt sich mit Grippe-wie Symptome und ein hohes Fieber dar, entwickelt einen septicemic purpurroten Hautausschlag, schnell wird unempfänglich und kann innerhalb der Stunden des Angriffes sterben. Die Sterblichkeitkinetik für Kinder mit strenger Krankheit kann 30% oder mehr sein. Unter Überlebenden sind amputations der Extremitäten und/oder permanente neurologische Beschädigung häufige bedeutende Komplikationen.

Warum beendet diese Krankheit oder maim so schnell? Das meningococcus- Bakterium, wie alles gramnegative Bakterium, verbindet in ihren giftigen Molekülen der Zelle Wände, die Endotoxine genannt werden, die eine Durchgehenreaktion durch das immune System des Opfers starten können. Diese " entzündliche Kaskade " kann weitverbreitete Beschädigung der $blutgefässe verursachen und zu einen Fall führen im Blutdruck (Schlag), in Organausfall, in der Nekrose der Haut und in den Extremitäten und im Tod. Weil die Krankheit so schnell weiterkommt, ist es wichtig, auf die Symptome aufmerksam zu sein und medizinische Behandlung sofort zu erhalten.

Wie ist Common diese Krankheit? Ausdehnung in Europa und die Vereinigten Staaten hat zwischen ungefähr 1-3 Fälle pro Bevölkerung 100.000 seit der letzten großen Epidemie in den vierziger Jahren geschwankt. 1995 gab es ungefähr 3000 US-Fälle Meningokokkenkrankheit. Im Vereinigten Königreich gab es auch ungefähr 3000 Fälle und stellte eine erheblich häufigere Ausdehnung als in den Vereinigten Staaten dar. Meningokokkenkrankheit ist, mit einer häufigeren Ausdehnung in der Nordhemisphäre in Winter und Frühling saisonal. Ausbrüche sind häufigeres Untergedrängt, Niedrigfeuchtigkeit Bedingungen, wie in lebhafte Klassenzimmer, wenn Atmungsinfektion leicht verbritten wird.

Wie wird die Krankheit behandelt? Das Bakterium wird betriebsbereit durch first-line Antibiotika beendet, aber es gibt keine aktuelle Behandlung für die giftige entzündliche Kaskade, die durch das Bakterium anders als Lebensdauer-unterstützende intensive Obacht gestartet wird. Es gibt zur Zeit kein praktisches großräumiges Schutzimpfungprogramm.

XOMA Corporation hat klinische Versuche mit einer neuen Untersuchungsdroge geleitet, die Neuprex(tm) (rBPI-21) genannt wird, für die Behandlung des strengen pädiatrischen meningococcemia. Neuprex(tm) wird von BPI (Bactericidal-/Permeability-Increasingprotein), ein Host-defenseprotein berechnet, das in den menschlichen weißen Blutzellen produziert wird. Neuprex(tm) beendet gramnegatives Bakterium wie N.-meningitidis und bindet an bakterielles Endotoxin, und das resultiert in seiner Neutralisation und erhöht seinen Abstand vom Körper (sehen Sie auch BPI- backgrounder).

Eine open-label klinische Studie von Neuprex(tm) wurde 1995-96 bei streng kranken pädiatrischen meningococcemiapatienten geleitet. Von 26 Patienten, die die Droge empfingen, nur man starb. Unter einer Kennzeichnung Subpart E (eine FDA beschleunigte Zustimmung programmieren, damit Drogen lebensbedrohende Krankheiten behandeln), leitet XOMA jetzt einen Angel (für FDA-Zustimmung) klinischen Versuch der Phase III, der die Droge in den mehrfachen medizinischen Mitten in den Vereinigten Staaten, in Kanada und im Vereinigten Königreich prüft.

[BigLinus]

Hier das Original:

Meningococcemia Fact Sheet
What is meningococcemia? Known in the UK and Europe as meningococcal septicemia, this is one of the few bacterial diseases that can kill an infected person within hours. Between 60-90% of all cases occur in children, and children under five are particularly at risk.

What causes this disease? It is caused by the same meningococcus bacteria, Neisseria meningitidis, that are the most common cause of the more familiar disease, meningitis. In meningitis, the bacteria cause inflammation of the membranes that surround the brain and spinal cord, manifested by a characteristic stiff neck and high fever. Meningitis responds rapidly to antibiotic treatment and permanent damage is rare.

How is meningococcemia different? In meningococcemia the bacteria invade the bloodstream. An infected child presents with flu-like symptoms and a high fever, develops a septicemic purple rash, rapidly becomes unresponsive and may die within hours of onset. The mortality rate for children with severe disease can be 30% or more. Among survivors, amputations of extremities and/or permanent neurological damage are frequent significant complications.

Why does this disease kill or maim so swiftly? The meningococcus bacteria, like all gram-negative bacteria, incorporate in their cell walls poisonous molecules called endotoxins, which may trigger a runaway reaction by the victim`s immune system. This "inflammatory cascade" can cause widespread damage to blood vessels, leading to a fall in blood pressure (shock), organ failure, necrosis of skin and extremities and death. Because the disease progresses so quickly, it is important to be alert to the symptoms and get medical care immediately.

How common is this disease? Incidence in Europe and the United States has varied between about 1-3 cases per 100,000 population since the last large epidemic in the 1940s. In 1995 there were about 3000 U.S. cases of meningococcal disease. In the United Kingdom there were also about 3000 cases, representing a significantly higher incidence than in the United States. Meningococcal disease is seasonal, with a higher incidence in the Northern Hemisphere in winter and spring. Outbreaks are more frequent under crowded, low-humidity conditions, such as in heated classrooms, when respiratory infections are easily spread.

How is the disease treated? The bacteria are readily killed by first-line antibiotics, but there is no current treatment for the toxic inflammatory cascade triggered by the bacteria other than life-supportive intensive care. There is at present no practical large-scale vaccination program.

XOMA Corporation has been conducting clinical trials with an investigational new drug called Neuprex(tm) (rBPI-21), for the treatment of severe pediatric meningococcemia. Neuprex(tm) is derived from BPI (Bactericidal/Permeability-Increasing protein), a host-defense protein produced in human white blood cells. Neuprex(tm) kills gram-negative bacteria like N. meningitidis and binds to bacterial endotoxin, resulting in its neutralization and enhancing its clearance from the body (see also BPI backgrounder).

An open-label clinical study of Neuprex(tm) was conducted in 1995-96 in severely ill pediatric meningococcemia patients. Of 26 patients who received the drug, only one died. Under a Subpart E Designation (an FDA accelerated approval program for drugs to treat life-threatening illnesses) XOMA is now conducting a pivotal (for FDA approval) Phase III clinical trial testing the drug in multiple medical centers in the United States, Canada, and the United Kingdom.

[BrooklynONE]

meningokokken verursachen hirnhautentzündung (meningitis). symptome grippeähnlich mit nackensteifigkeit, deshalb häufig zu spät bzw. falsch diagnostiziert. wenn keine rechtzeitige behandlung mit antibiotika erfolgt, ist der krankheitsverlauf tödlich.

[BigLinus]

Ist die Trendwende bei den `BioTechs` da ?
XOMA ist kurz vor Börsenschluß in den USA um 15,56% gestiegen.

Weitere ínteressante News könnt ihr bei www.cnnfn.marketguide.com und bei www.bioivest.com erhalten.

Ciao

[BigLinus]

Antibiotischer Widerstand in den Mikroben
Vor das Aufkommen der leistungsfähigen Antibiotika über halbem einem Jahrhundert drastisch änderte die Abgleichung der Energie zwischen Menschen und Mikroben. Für einige Dekaden nach der Einleitung des Penicillins in den vierziger Jahren, aussah die Gesamteroberung der ansteckenden Krankheit unmittelbar drohend nd. Jedoch verschworen der weitverbreitete Gebrauch der Antibiotika mit der erstaunlichen Entwicklungsflexibilität der Mikroben weg snatch diesen Sieg.

Eine zunehmende Anzahl von Bakterium, Pilzen und anderen Mikroben entwickeln Widerstand zu den Antibiotika. Besonders in den Krankenhäusern (und unter Patienten deren immune Systeme durch AIDS, Chemotherapie oder immunosuppressive Drogen verglichen), auftaucht beständige (MDR) Infektion der mehrfachen Droge ht. Dieser Prozeß fortfährt jetzt mit einer Kinetik schneller als die Einleitung der neuen Antibiotika uen.

Wie geschah dieses und was kann über es getan werden?

Mikroben gelebt auf diesem Planeten viele Hunderte Millionen Jahre länger, als wir haben. Bakterium insbesondere angepaßt einer außerordentlichen Strecke der Bedingungen und der entwickelten Verteidigung gegen alle Sortierungen von Klimadrohungen -. Vom bakteriellen Gesichtspunkt ist der menschliche Körper ein anderer Hauptrechner zum Kolonisieren gerade, und Antibiotika sind eine andere giftige Klimadrohung zum Widerstehen gerade. Für organismen mit Bevölkerungen, die bereits solchen extremen Klimas angepaßt, wie kochender Schwefel entspringt, war das Lernen, mit Antibiotika zu leben unvermeidlich.

Auftauchender Widerstand
Overuse der Antibiotika beigetragen zum Problem n. In neu-industrialisierten Nationen beigetragen unterschiedsloser Gebrauch der Antibiotika zum Hervortreten der MDR-Belastungen des Bakteriums wie Pseudomonas, Streptokokke und Staphylokokkend. Einige Länder, einschließlich der Vereinigten Staaten, sehen auch Belastungen der Tuberkulose (TB), die gegen alle vorhandenen TB-Drogen beständig sind. Diese beständigen Belastungen entwickelt im großen Teil, weil viele TB-Patienten den angeforderten langatmigen Kurs der antibiotischen Behandlung durchführen nicht können. Neue Zunahmen der beständigen bakteriellen Ohr- und Kurveinfektion in den Kindern können durch nicht angebrachten Gebrauch der Antibiotika verbittert worden sein, Vireninfektion zu behandeln. Mehr Stören ist die Tendenz, Zweitzeile und Letztrücksortierungantibiotika anstatt der first-line Antibiotika vorzuschreiben, selbst wenn es keinen Grund gibt, Widerstand zu den älteren Drogen zu vermuten. In bestimmten Fällen wie rückläufige Lungenflügelinfektion bei cystic Fibrosispatienten, haben Ärzte keine Wahl aber, antibiotische Behandlung zu entwickeln, bis das Ansteckenbakterium gegen alle vorhandenen Antibiotika beständig wird.

Mit dem Hervortreten der antibiotikaresistenten organismen, verloren die medizinische Gemeinschaft Boden, wenn sie eine permanente Eroberung der Mikrobeninfektion erzielte. Aber viel erlernt worden im Prozeß. Mit einem tieferen Verständnis der Mikroben und ihrer Einheiten des Widerstandes, fortfährt die biomedizinische Gemeinschaft che, eine ausgedehnte Reihe Verteidigung gegen sie einzuhängen. Solche Verteidigung umfaßt erneuerte Aufmerksamkeit zu den medizinischen Grundlagen, wie Massen des öffentlichen Gesundheitswesens z.B. in den HIV-infectedbevölkerungen, die gewordene Nährböden für beständige Mikroben haben.

In den Krankenhäusern in denen die beständigsten Mikroben die verletzbarsten Patienten anstecken können, es ein Wiederaufleben des Interesses geben, grundlegende Techniken (wie Hand-hand-washing) für das Verhindern der Verbreitung der Infektion an wiederzubeleben und an zu verbessern. Ärzte, Krankenschwesterpraktiker und Apotheker werden auch dem Wert der vorsichtigeren Verordnungpraxis bewußter.

Pharmazeutische IndustrieAntwort
Pharmazeutische und Biotechnologiefirmen entwickeln Romanprodukte, um Widerstand zu überwinden. Besseres Verständnis der Mikrobiologie und der molekularen Genetik des Mikrobenwiderstandes führt zu die Entwicklung eines neuen Erzeugung von Anti-microbials, die unterschiedliche Einheiten der Tätigkeit benutzen, um Bakterium oder Pilze zu beenden. Neue Waffen im Kampf gegen Mikrobeninfektion mit.einschließen auch antibiotische Hilfen, die Drogen hilfen, die in den Antibiotika kombiniert, um ihre Energie zu erhöhen oder zu erneuern.

Antibiotischer Widerstand ist ein wichtiger Bereich der Forschung für XOMA und auch für die US-Nahrung und die Drogeleitung (FDA). Im Juli 1996, Klaps Scannon, MD, PhD-, XOMA`s-wissenschaftlicher und medizinischen hauptsächlichoffizier, behandelte Ausgaben hinsichtlich sind der Entwicklung der antiinfektiösen Produkte, MDR-Mikroben bei einer geöffneten Sitzung der Gutachterkommission der antiinfektiösen Drogen FDA`s zu bekämpfen.

XOMA`s-Bemühungen Gegen Widerstand
XOMA aufbaut aktuell eine Rohrleitung der neuen anti-infectives von einem menschlichen benannten Host-defenseprotein BPI (bactericidal-/permeability-increasingprotein). BPI beendet Bakterium mit einem Modus der Tätigkeit unterschiedlich zu herkömmlichen Antibiotika, und BPI-derivedproteine gezeigt worden, um die Energie der Antibiotika zu erhöhen und in einigen Fällen beständige organismen empfindlilch gebildet.

Eine zunehmende Anzahl von antibiotikaresistenter Auge Infektion verursacht Interesse in der Augengemeinschaft. Im Juni 1999, anfing XOMA eine Teilhaberschaft mit Allergan t, um antiinfektiöse Augenprodukte zu entwickeln, die rBPI mit Antibiotika kombinieren. Beide Firmen bestätigt frühere Entdeckungen, die rBPI mit ofloxacin (ein augenfälliges Antibiotikum in weitverbreitetem Gebrauch) gegen verschiedene Belastungen der gramnegativen und grampositiven Sorten des Bakteriums synergiert. Die Kombination kann bakteriellen Widerstand zum Antibiotikum alleine in vielen Fällen aufheben. Gegründet auf diesen Entdeckungen Allergan entwickelt rBPI-Kombination antiinfektiöse Produkte und plant, klinisches anzumelden, 2000 spät innen prüfend oder früh in 2001.

[BigLinus]

XOMA in den USA um $1, 5/16 gestiegen. Schlußstand: $9,75.

[BigLinus]

Peter B. Davis, der Vice-President of Finance and CFO of XOMA hat in einem Interview bestätigt, daß XOMA im Februar ca. 6,1 Mio Anteile für ca. $30,7 Mio an eine Anzahl institutioneller Anleger verkauft hat:

"We are very pleased with the reception we received for this financing," said Peter B. Davis, Vice President of Finance and CFO of XOMA. "We attracted high-quality institutional investors and demand was such that we increased the funding above our original target level. The collaboration, licensing and supply agreements concluded in the past year with Genentech, Allergan and, most recently, Baxter have reduced our burn rate. These relationships plus this financing improve our financial position considerably over that of recent
years."

"This week`s financing represents a significant increase in our level of institutional investment," said Jack Castello, Chairman, President and CEO of XOMA. "We now have approximately two years of cash on hand to support continuing research on promising opportunities that could further enhance the value of the company."

Financing proceeds will be used primarily to fund development of products from XOMA`s monoclonal antibody and BPI (bactericidal/permeability-increasing protein) development platforms. Monoclonal antibody products in XOMA`s research pipeline include ING-1, an antibody that may be useful in treating a variety of solid tumor cancers, and Genimune(TM), a targeted gelonin fusion product
candidate for treatment of immune cell cancers and autoimmune diseases. Internal BPI development programs include Mycoprex(TM), a BPI-derived fungicidal compound, and anti-angiogenic BPI peptide-derived compounds.

XOMA develops and manufactures biopharmaceuticals at facilities located in Berkeley and Santa Monica, Calif. Medical targets include infectious diseases, immunologic and inflammatory disorders, and cancer. The Company has extensive experience developing monoclonal antibodies. XOMA is collaborating with Genentech in developing the anti-CD11a humanized monoclonal antibody product. A Phase III trial was started in patients with moderate to severe plaque psoriasis
in December 1999 and plans have been announced to perform a Phase I/II study in kidney transplant patients. In addition to the ING-1 and Genimune(TM) products, XOMA owns a patented method for antibody humanization, and has developed a cell expression system for manufacturing recombinant proteins (including antibodies) that has been licensed to more than 15 biotechnology and pharmaceutical
companies worldwide.

Tja, da kein Vermögensverwalter auf längere Zeit das Geld seiner Anleger vernichten will (dieser Beruf ist in den USA ganz anders angesehen als bei uns), werden sich diese `ihr` Engagement sicher sehr überlegt haben.

[BigLinus]

DNA) XOMA Initiates Phase I/II Clinical Study of Anti-CD11a in KidneyTransplant Patients
Thu Mar 30 08:17:00 EST 2000

BERKELEY, Calif., Mar 30, 2000 (BW HealthWire) -- XOMA Ltd. (Nasdaq:XOMA) today announced the initiation of a Phase I/II clinical study of anti-CD11a in kidney transplant recipients.

XOMA is collaborating with Genentech, Inc. (NYSENA) to develop this
recombinant, humanized monoclonal antibody designed to selectively inhibit immune system T cells. This is the second indication being evaluated for this investigational antibody; a Phase III trial of anti-CD11a in patients with moderate-to-severe plaque psoriasis began in December 1999.

"T cells are involved in the immune system`s rejection of transplanted organs as well as in autoimmune diseases like psoriasis," said Marvin Garovoy, MD, Vice President of Clinical and Medical Affairs at XOMA. "We believe that anti-CD11a may have potential advantages over immunosuppressive drugs currently used to
prevent organ transplant rejection. Initially, we will study the antibody in combination with standard immunosuppressive drugs to test its safety in this population and to see if it further reduces graft rejection. Ultimately, anti-CD11a may allow reduced use of other agents, potentially making for a safer and more effective therapeutic regimen."

When an organ such as a kidney is transplanted from an unrelated donor, the recipient`s immune system typically identifies the grafted organ as a foreign body. The host`s immune system T cells then attack the transplanted organ, a process called "rejection" that destroys the new organ or prevents it from functioning. To prevent rejection of the transplanted organ, patients receive drugs to suppress their immune systems. However, even with such treatments, 20-30% of grafts experience rejection episodes. Moreover, immunosuppressive drugs can have serious side effects, such as kidney toxicity, and make patients
vulnerable to opportunistic infections. T cells are also involved in autoimmune diseases such as psoriasis, where they interact inappropriately with the host`s own skin cells, leading to inflammation and other symptoms.

XOMA develops and manufactures biopharmaceuticals in Berkeley and Santa Monica, California. Medical targets include infectious diseases, immunologic and inflammatory disorders, and cancer. The Company`s extensive experience developing monoclonal antibodies is reflected in the Genentech anti-CD11a collaboration and its own ING-1 and Genimune(TM) products. XOMA has a patented Human Engineering method for "humanizing" antibodies and a proprietary cell expression system for manufacturing recombinant proteins (including antibodies)
that has been licensed to nearly 20 biotechnology and pharmaceutical companies worldwide. The Company`s infectious disease product development platform is BPI (bactericidal/permeability-increasing protein), a human protein with multiple anti-infective properties and part of the body`s defenses against microbial infection. BPI was discovered at New York University School of Medicine (NYU) by Peter Elsbach, MD, and Jerrold Weiss, PhD. XOMA has collaborated with NYU since 1991 to extend and apply BPI-related research to pharmaceutical development. The Company has agreements with The Hyland Immuno division of Baxter Healthcare Corporation and with Allergan to develop BPI-related products. For more information, visit XOMA`s web site at www.xoma.com

The statements made in this news release related to collaborative and licensing relationships, product development and clinical testing, or that otherwise relate to future periods, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies
engaged in the development of new products in a regulated market. These risks, including those related to the timing or results of pending or future clinical trials, changes in the status of collaborative relationships, and actions by the U.S. Food and Drug Administration or the U.S. Patent and Trademark Office, are discussed in XOMA`s most recent annual reports on Form 10-K and in other SEC
filings. Consider such risks carefully in evaluating XOMA`s prospects.


Distributed via COMTEX.

Copyright (C) 2000 Business Wire. All rights reserved.

[BigLinus]

XOMA in den USA zum Wochende wieder gestiegen.
+ $0,5 auf $7,75 = + 6,90%

[fati]

Hilfe!!

Ich glaube ich verstehe hier etwas falsch. Die Xoma-Aktie fällt und fällt und fällt und hier ist nichts negatives drin zu lesen. Kann mir vielleicht einer sagen warum?

[BigLinus]

Hi fati,

wie bei allen BioTechs ist auch bei XOMA viel Fantasie drin. Und wie Du sicher bemerkt hast, sind in den letzten drei Wochen alle Technologiewerte und dabei insbesondere auch die BioTechs gefallen. Zum Teil liegen deren Verluste zum All-time-high bei über 50%. Auch XOMA lag zwischenzeitlich schon bei 16,5 EUR.

Nun liegt es an Dir. Glaubst Du an Deine damalige Entscheidung, dann wirst Du halten oder gar nachkaufen. Oder aber Du verkaufst und versuchst es bei einem niedrigeren Stand nochmals oder läßt ganz die Finger von XOMA.

Die Infos die ich hier (leider zum großteil in Englisch) gepostet habe, waren nicht zum pushen des Wertes gedacht, sondern zur Infogewinnung.

Also kann ich Dir nur raten, die verschiedenen Infos nochmals zu lesen und dann mußt Du Dich entscheiden.

Für mich kann ich nur sagen, daß sobald eine größere Menge Kapital frei wird (für meine Verhältnisse), dann kaufe ich XOMA nochmals nach.

Ciao BigLinus

[BigLinus]

Hi XOMA-Gemeinde,

in den voranstehenden Beiträgen, wie auch bei anderen BioTech-Werten, wird immer wieder von Phasen gesprochen, in denen sich ein Produkt befände.
Hier ein kurzer Aufsatz was die US Food and Drug Behörde (entspricht unserem Bundesgesundheitsamt) darunter versteht.

The Clinical Trial Process
The drug approval process starts in the laboratory. After discovering a promising compound, studies using the compound in cell cultures, isolated tissues, and laboratory animals are conducted. This gives researchers a pretty good idea of what to expect in human trials. On average, only one compound in a thousand will actually make it to human testing. Assuming the data is promising, the company makes the decision whether to begin the long and costly process of getting the compound to market. Since most drug companies have multiple candidates, the company must take into account the size of the potential patient population, whether the market for that particular drug is already well-served, and the company`s financial situation. Also, the patent protection for the drug, generally lasting 17 years, begins to tick once the compound begins pre-clinical trials. The pre-clinical trials for most drugs average about five years.

Assuming the company decides to pursue human studies, it must first submit an Investigational New Drug application to the FDA for approval. The IND becomes effective 30 days after receipt by the FDA (assuming the FDA does not require further information), and must be filed annually thereafter until the completion of clinical testing. The IND must provide pre-clinical data of sufficient quality to justify the testing of the drug in humans. About 85% of all IND applications move on to begin clinical trials. Assuming the company receives FDA go-ahead, the company will move the drug on to Phase 1 testing in human subjects. At this point, the compound has a one in five chance of eventually reaching the market, and will normally take another five to nine years to reach that destination.

Phase 1
Phase 1 trials concentrate on developing the drug`s safety profile. The human subjects in the study are normally healthy volunteers, though sometimes patients who have terminal illnesses and have no other therapeutic alternative will take part in Phase 1 studies as well. The sample is normally not more than 100 patients in Phase 1. The basic goal of Phase 1 is to determine how the drug is absorbed, distributed in the body, metabolized, and excreted. The duration of the drug`s effects are also measured. Phase 1 testing ranges from one to three years, on average.

Assuming the data from Phase 1 are positive and the safety of the compound is established, the drug moves on to Phase 2 testing. If the company moves on to begin Phase 2 trials, the drug`s chance of eventually making it to market improves to just under 30%.

Phase 2
Phase 2 trials consist of small, well-controlled experiments to continue to evaluate the drug`s safety and assess side effects. The drugs are given to volunteers (usually between 100 and 300 patients) who actually suffer from the disease or condition being targeted by the drug. This phase is where the optimal dosage of the drug is established. Also, statistical end points are established for the drug that represent the targeted favorable outcome of the study. The current standard of care for the medical condition can be used as a benchmark in setting the end point. Phase 2 trials last an average of two years.

A drug that moves on to begin Phase 3 testing has about a 60% chance of actually being approved by the FDA.

Phase 3
Phase 3 testing is intended to verify the effectiveness of the drug against the condition that it targets, based on the statistical end points established in Phase 2. The study also continues to build the safety profile of the drug and record possible side effects and adverse reactions resulting from long-term use. Phase 3 studies are tightly controlled, double-blind studies with a sample size of at least 1000 patients. If the drug proves to be effective in this stage, the trial is deemed successful (pivotal). Normally two pivotal trials are required to ensure the validity of the studies, although if the results are extremely strong, one may suffice. Phase 3 testing averages between three and four years.

Assuming the drug reaches the desirable end point in Phase 3 trials, the company will then file a New Drug Application, which can contain 100,000 pages of data supporting the efficacy and safety of the drug. At this point, the drug has better than a 70% chance of being approved by the FDA.

Approval of the NDA can take anywhere from two months to an extreme of several years (in the case that the FDA requests additional information), with an average wait of between 18 and 24 months. Upon approval, the company may begin to market and distribute the drug.

Phase 4
Once the drug is on the market, the company must continue to perform observational studies in an ongoing evaluation of the drug`s safety during routine use. The company also attempts to monitor any usage of the drug for conditions other than the approved medical indication. If the drug is being successfully used for off-label indications, the company will often initiate further clinical trials for those indications in order to widen the potential market for the drug. The company cannot advertise or endorse off-market use of the drug, however.

Ich hoffe der englische Text ist für Euch relativ gut verständlich und Ihr könnt damit ein BioTech-Wert besser einschätzen.

Ciao BigLinus

[BigLinus]

Hi XOMA-Gemeinde,

nach dem gestrigen Ende der Talfahrt (kleines Plus), legt XOMA in den USA erneut zu. Nachdem ca. 3/4 des US-Börsentags vorüber ist, steht XOMA bei $8. Dies ist ein Plus von $1,25 und entspricht einer Steigerung von 18,52%.

Ciao BigLinus

[BigLinus]

Tuesday April 4, 1:54 pm Eastern Time
Company Press Release
SOURCE: The American Stock Exchange
Amex to Trade Options on Nanophase Technologies Corporation, NeoRx Corporation, Repligen Corporation, and XOMA Ltd.

NEW YORK, April 4 /PRNewswire/ -- The American Stock Exchange will launch trading in options on the Nasdaq National Market-listed stocks Nanophase Technologies Corporation (Options Symbol: NNU/ Stock Symbol: NANX), NeoRx Corporation (Options Symbol: XUO/ Stock Symbol: NERX), Repligen Corporation (Options Symbol: RGU/ Stock Symbol: RGEN), and XOMA Ltd. (Options Symbol: MBU/ Stock Symbol: XOMA) on Monday, April 10, 2000.

XOMA Ltd. options will open with strike prices of 5, 7-1/2, 10 and position limits of 75,000 contracts. The options will trade on the February expiration cycle, with initial expirations in May, June, August and November. The specialist is Charlton, SLK. XOMA, a biopharmaceutical company, develops and manufactures genetically engineered protein, peptide, and antibody pharmaceuticals.

The American Stock Exchange trades options on 23 broad-based and sector indexes and more than 2,000 domestic and foreign stocks, as well as Long-term Equity AnticiPation Securities® (LEAPS®) on over 270 stocks. Amex is a leader in listing warrants on indexes, hybrid instruments and other structured products. The Amex is home to the Index Share(TM) Marketplace, which includes SPDRs®, Select Sector SPDRs®, DIAMONDS®, MidCap SPDRs(TM), WEBS(TM) and Nasdaq-100 Index Tracking Stock(SM).

SOURCE: The American Stock Exchange

[BigLinus]

Hi XOMA-Gemeinde,
CNBC recommended XOMA for buy.
Nach etwas mehr als der Hälfte des US Börsentags steht XOMA erneut im Plus. + $ 1 29/64 = + 17,97%.
Ciao BigLinus

[BigLinus]

Xoma Limited
Last 9 3/8
Open 8 7/8
High 10 1/8
Bid 9 9/32
52 Week High 16
EPS -0.88
Shares Outstanding 64.72M
PE Ratio N/A
Change + 1 3/8
% Change + 17 3/16%
Low 8 5/16
Ask 9 3/8
52 Week Low 2
Volume 2.63M
Market Cap. 517.74M
As Of (E.T.) 4/7/00 13:53
Exchange NASDAQ

[BigLinus]

Schlußstand XOMA in den USA: $9,325.

[BigLinus]

Xoma Limited
Last 6 1/2
Open 7 7/8
High 7 7/8
Bid 6 7/16
52 Week High 16
EPS -0.88
Shares Outstanding 64.72M
PE Ratio N/A
Change - 1 11/32
% Change -17.13%
Low 6 1/8
Ask 7
52 Week Low 2
Volume 1.02M
Market Cap. 507.63M
As Of (E.T.) 4/12/00 16:00
Exchange NASDAQ

[BigLinus]

Hi XOMA-Gemeinde,

hier ist eine Übersicht der letzten beantragten und genehmigten Patente von XOMA beim US Patentamt von Ende Dezember 1998 an.

Patent Issued Title
US06017881 01/25/2000 Method of treating conditions associated
with intestinal ischemia/reperfusion
US06013631 01/11/2000 Bactericidal/permeability-increasing protein
(BPI) deletion analogs
US06013629 01/11/2000 Anti-protozoan methods and materials
US05990086 11/23/1999 Therapeutic uses of BPI protein products for
human meningococcemia
US05990082 11/23/1999 Uses of lipopolysaccharide binding protein
US05955427 09/21/1999 Pharmaceutical composition
US05952302 09/14/1999 Human therapeutic uses of BPI protein
products
US05945399 08/31/1999 Therapeutic uses of BPI protein products in
humans with hemorrhage due to trauma
US05935930 08/10/1999 Antithrombotic materials and methods
US05932544 08/03/1999 Bactericidal/permeability-increasing protein
(BPI) compositions
US05912228 06/15/1999 Therapeutic compositions comprising
bactericidal/permeability-increasing (BPI)
protein products
US05891618 04/06/1999 Method for quantifying LBP in body fluids
US05888973 03/30/1999 Anti-chlamydial uses of BPI protein products
US05869619 02/09/1999 Modified antibody variable domains
US05858974 01/12/1999 Anti-fungal peptides
US05856438 01/05/1999 Biologically active peptides from functional
domains of bactericidal/permeability-
increasing protein and uses thereof
US05856302 01/05/1999 Therapeutic uses of bactericidal/
permeability-increasing protein dimer
products
US05854214 12/29/1998 Therapeutic uses of bactericidal/
permeability increasing protein products
US05851802 12/22/1998 Methods for recombinant microbial production
of fusion proteins and BPI-derived peptides
US05846818 12/08/1998 Pectate lyase signal sequence

[Minolta]

Hi Big Linus! Erstmal vielen Dank, für Deine zahlreichen Infos. Sicher muss man bei Biotech-Werten viel Geduld mitbringen, denn bis ein Medikament es bis zur Zulassung gebracht hat, ist ein ewig weiter Weg. Etwas frustrierend ist es im Moment aber schon, wenn zumindest mal die 10€ halten würden, das wäre ein Anfang. Bin zu spät eingestiegen, bei 13,5€. Vielleicht kaufe ich nochmal nach, weiss ich aber noch nicht. Gruss Minolta

[BigLinus]

Hi Minolta,

da muß ich Dir leider zustimmen. Es ist nicht leicht dem Ratschlag von Kostolany zu folgen: Kaufen, 20 Jahre unbeobachtet liegen lassen und dann genießen.
Ich bin erstmals bei EUR 12,25 rein und habe dann nochmals bei EUR 8,50 nachgekauft. Aber rot bleibt rot. Und die heutige Entwicklung macht es auch nicht leichter.

Xoma Limited
Last 7 1/8
Open 7 1/32
High 7 3/8
Bid 7
52 Week High 16
EPS -0.88
Shares Outstanding 64.72M
PE Ratio N/A
Change + 5/8
% Change + 9.62%
Low 6 1/4
Ask 7 1/8
52 Week Low 2
Volume 475.90K
Market Cap. 420.66M
As Of (E.T.) 4/13/00 11:50
Exchange NASDAQ

Naja, vielleicht helfen uns heute mal die Leute auf der anderen Seite vom Teich. Nach den Kurseinbrüchen wird es langsam wieder Zeit. Vielleicht finde ich auch noch etwas interessantes bei den US-Patenten von XOMA.

Ansonsten bleibt es beim alten Wahlspruch: Hy folks and friends, keep the fire burning !!!!!!

Ciao BigLinus

[BigLinus]

Hi Xoma-Gemeinde,
nach der rasanten Abwärtsrally der letzten 3-4 Wochen, hört man kaum mehr etwas von Euch. Oder habt Ihr Euch von XOMA getrennt? Es wird Zeit, daß ihr Euch mal wieder rührt.

- Wie seht Ihr die Zukunft von XOMA?
- Seit Ihr nachwievor so optimistisch?
- Bleibt Ihr bei Euren Kursvorstellungen zum Jahresende?
- Wie lauten Eure neuen Kursvorstellungen zum Jahresende?

Dies richtet sich an alle, insbesondere aber an Mr.Gruendlich, Minolta, Saltus2, bartel1, Doc Hollywood, kemjan1, geldfuchs, MasterEd, Greenshook, fati, mahatma.
Sollte ich einen vergessen haben, dann entschuldige ich mich. Das war nicht meine Absicht.

Ciao BigLinus

[BigLinus]